The 2022 Gradient Prize
$3000 in prizes, sponsored by Immunai
After a successful 2021 run, we decided to continue the Gradient prize for 2022, this time featuring a total prize pool of $3000 (triple last year). We will be awarding prizes for submissions received between January 1 - April 1, 2022. If you’ve ever been itching to write something with the Gradient, now is your chance! To enter the contest, just fill out our writing interest form and indicate interest in the contest in your submission. More details here.
Prize allocation
In total, we will award $3000 in prizes for the best new article submissions received between Jan 1 and April 1, 2022.
Winner: $1500
Two runners-up: $750 each
Immunai
Immunai is a techbio company (based in NYC and Tel Aviv) that uses single-cell genomics and machine learning to develop novel cancer and autoimmunity drugs and reprogram the immune system. Immunai has created a new systemic approach for drug discovery and development by building a proprietary platform that combines best-in-class single-cell genomic methods, artificial intelligence (based on tens of millions of cells and other data), and immunology. They are developing the first modern ML methods (think a “Cell BERT”) for cancer immunotherapy drug discovery, and their key advantage is ~ 10x more high-dimensional singe-cell data than most other methods (think ~ 1TB of data per 1 mL of blood).
Immunai’s team of ML Scientists and immunologists then uses this data to surface insights such as mechanisms of action and resistance, allowing the company to develop new therapies and evaluate and validate preclinical assets. For more information, visit www.immunai.com, or read one of their blogposts here.